

Application No.
Amendment Dated
Reply to Office Action of


10/088,352
27th June 2005
28th November 2005

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A compound of formula (I)



(I)

or a salt, or phosphate ester, or amide thereof;

where X is O, or S, S(O) or S(O)₂; or NR¹⁰ where R¹⁰ is hydrogen or C₁₋₆alkyl;

R⁵ is a group OR¹¹, NR¹²R¹³ or SR¹¹ where R¹¹, R¹² and R¹³ are independently selected from

hydrogen, optionally substituted hydrocarbyl where optional substituents are functional groups,

or optionally substituted heterocyclic groups where optional substituents are functional groups or

hydrocarbyl, and R¹² and R¹³ may additionally form together with the nitrogen atom to which they

are attached, an optionally substituted aromatic or non-aromatic heterocyclic ring which may

contain further heteroatoms: [[.]]

R⁶ and R⁷ are independently selected from hydrogen or hydrocarbyl;

R⁸ and R⁹ are independently selected from hydrogen, halo, C₁₋₄alkyl, C₁₋₄alkoxy,

C₁₋₄alkoxymethyl, di(C₁₋₄alkoxy)methyl, C₁₋₄alkanoyl, trifluoromethyl, cyano, amino, C₂₋₅alkenyl,

C₂₋₅alkynyl, a phenyl group, a benzyl group or a 5-6-membered heterocyclic group with 1-3

heteroatoms [[.]] selected independently from O, S and N, which heterocyclic group may be

aromatic or non-aromatic and may be saturated, linked via a ring carbon or nitrogen atom, or

unsaturated, linked via a ring carbon atom, [[.]] and which phenyl, benzyl or heterocyclic group

may bear on one or more ring carbon atoms up to 5 substituents selected from hydroxy,

halogeno, C₁₋₃alkyl, C₁₋₃alkoxy, C₁₋₃alkanoyloxy, trifluoromethyl, cyano, amino, nitro,

C₂₋₄alkanoyl, C₁₋₄alkanoylamino, C₁₋₄alkoxycarbonyl, C₁₋₄alkylsulphanyl, C₁₋₄alkylsulphinyl,

C₁₋₄alkylsulphonyl, carbamoyl, N-C₁₋₄alkylcarbamoyl, N,N-di(C₁₋₄alkyl)carbamoyl,

BEST AVAILABLE COPY

Application No.
Amendment Dated
Reply to Office Action of

10/088,352
27th June 2005
28th November 2005

aminosulphonyl, N-C₁₋₄alkylaminosulphonyl, N,N-di(C₁₋₄alkyl)aminosulphonyl, C₁₋₄alkylsulphonylamino, and a saturated heterocyclic group selected from morpholino, thiomorpholino, pyrrolidinyl, piperazinyl, piperidinyl, imidazolidinyl and pyrazolidinyl, which saturated heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, C₁₋₃alkyl, C₁₋₃alkoxy, C₁₋₃alkanoyloxy, trifluoromethyl, cyano, amino, nitro and C₁₋₄alkoxycarbonyl; [I.] and R¹, R², R³, R⁴ are independently selected from halogeno, cyano, nitro, C₁₋₃alkylsulphonyl, -N(OH)R¹⁴ [I.] wherein R¹⁴ is hydrogen [I.] or C₁₋₃alkyl, [I.] or R¹⁶X¹ wherein X¹ represents a direct bond, -O-, -CH₂-, -OC(O)-, -C(O)-, -S-, -SO-, -SO₂-, -NR¹⁷C(O)-, -C(O)NR¹⁸-, -SO₂NR¹⁹-, -NR²⁰SO₂- or -NR²¹-, wherein R¹⁷, R¹⁸, R¹⁹, R²⁰ and R²¹ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl, [I.] and R¹⁶ is hydrogen, optionally substituted hydrocarbyl, optionally substituted heterocyclyl or optionally substituted alkoxy selected from one of the following twenty-two groups:

1) hydrogen or C₁₋₅alkyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, oxiranyl, fluoro, chloro, bromo, amino, C₁₋₃alkyl, and trifluoromethyl;

2) -R^aX²C(O)R²²; wherein X² represents -O- or -NR²³-, in which R²³ represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl and R²² represents C₁₋₃alkyl, -NR²⁴R²⁵ or -OR²⁶, wherein R²⁴, R²⁵ and R²⁶ which may be the same or different each represents hydrogen, C₁₋₅alkyl, hydroxyC₁₋₅alkyl or C₁₋₃alkoxyC₂₋₃alkyl;

3) -R^bX³R²⁷; wherein X³ represents -O-, C(O)-, -S-, -SO-, -SO₂-, -OC(O)-, -NR²⁸C(O)-, -NR²⁸C(O)O-, -C(O)NR²⁹-, C(O)NR²⁹-, -SO₂NR³⁰-, -NR³¹SO₂- or -NR³²-, wherein R²⁸, R²⁹, R³⁰, R³¹ and R³² each independently represents hydrogen, C₁₋₃alkyl, hydroxy C₁₋₄alkyl or C₁₋₃alkoxyC₂₋₃alkyl, and R²⁷ represents hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl or a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which C₁₋₆alkyl group may bear 1, 2 or 3 substituents selected from oxo, hydroxy, halogeno, cyclopropyl, amino, C₁₋₄alkylamino, C₁₋₄alkanoyldi-C₁₋₄alkylamino, C₁₋₄alkylthio, C₁₋₄alkoxy and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C₁₋₄cyanoalkyl, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkylsulphonylC₁₋₄alkyl, C₁₋₄alkoxycarbonyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkoxy, di(C₁₋₄alkyl)aminoC₁₋₄alkoxy and a group -(-O-)(R^b)_qD, wherein f is 0 or 1, q is 0 or 1 and D is a cyclic group selected from C₃₋₆cycloalkyl group, an aryl group or a 5-6-membered saturated or unsaturated heterocyclic group with 1-2

Application No.
Amendment Dated
Reply to Office Action of

10/088,352
27th June 2005
28th November 2005

heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from halo or C₁₋₄alkyl;

4) -R^cX⁴R^cX⁵R³⁵, wherein X⁴ and X⁵ which may be the same or different are each -O-, C(O), -S-, -SO-, -SO₂-, -NR³⁶C(O)-, -NR³⁶C(O)O-, -C(O)NR³⁷-, -C(O)ONR³⁷-, -SO₂NR³⁸-, -NR³⁹SO₂- or -NR⁴⁰-, wherein R³⁵, R³⁶, R³⁷, R³⁸ and R⁴⁰ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl, and R³⁵ represents hydrogen, C₁₋₃alkyl, hydroxyC₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl;

5) R⁴¹, wherein R⁴¹ is a 4-6-membered cycloalkyl or saturated heterocyclic ring, linked via carbon or nitrogen, with 1-2 heteroatoms, selected independently from O, S and N, which cycloalkyl or heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, cycloalkyl or heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C₁₋₄alkyl, hydroxyC₁₋₄alkyl, cyanoC₁₋₄alkyl, cyclopropyl, C₁₋₄alkylsulphonylC₁₋₄alkyl, C₁₋₄alkoxycarbonyl, carboxamido, C₁₋₄aminoalkyl, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, C₁₋₄alkanoyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkoxy, di(C₁₋₄alkyl)aminoC₁₋₄alkoxy nitro, amino, C₁₋₄alkoxy, C₁₋₄hydroxyalkoxy, carboxy, trifluoromethyl, -C(O)NR⁴³R⁴⁴-, -NR⁴⁵C(O)R⁴⁶-, wherein R⁴³, R⁴⁴, R⁴⁵ and R⁴⁶, which may be the same or different, each represents hydrogen, C₁₋₄alkyl, hydroxyC₁₋₄alkyl or C₁₋₃alkoxyC₂₋₃alkyl and a group -(O)_f(C₁₋₄alkyl)_gringD, wherein f is 0 or 1, g is 0 or 1 and D is a cyclic group selected from C₃₋₆cycloalkyl, aryl or 5-6-membered saturated or unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from halo and C₁₋₄alkyl;

6) -R^dR⁴¹, wherein R⁴¹ is as defined hereinbefore;

7) -R^eR⁴¹, wherein R⁴¹ is as defined hereinbefore;

8) -R^fR⁴¹, wherein R⁴¹ is as defined hereinbefore;

9) R⁴², wherein R⁴² represents a phenyl group or a 5-6-membered aromatic heterocyclic group, linked via carbon or nitrogen, with 1-3 heteroatoms selected from O, N and S, which phenyl or aromatic heterocyclic group may carry up to 5 substituents selected from hydroxy, nitro, halogeno, amino, C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄hydroxyalkyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, C₁₋₄hydroxyalkoxy, oxo, cyanoC₁₋₄alkyl, cyclopropyl, C₁₋₄alkylsulphonylC₁₋₄alkyl, C₁₋₄alkoxycarbonyl, di(C₁₋₄alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, C₁₋₄alkanoyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkoxy, di(C₁₋₄alkyl)aminoC₁₋₄alkoxy, carboxy, carboxamido, trifluoromethyl, cyano, -C(O)NR⁶⁹R⁷⁰-, -NR⁷¹C(O)R⁷²-, wherein R⁶⁹, R⁷⁰, R⁷¹ and R⁷², which may be the same or different, each represents hydrogen, C₁₋₄alkyl, hydroxyC₁₋₄alkyl or C₁₋₃alkoxyC₂₋₃alkyl, and a group -(O)_f(C₁₋₄alkyl)_gringD, wherein f is 0 or 1, g is 0 or 1 and ring D is a cyclic group selected from C₃₋₆cycloalkyl, aryl or 5-6-membered saturated or unsaturated

Application No.
Amendment Dated
Reply to Office Action of

10/088,352
27th June 2005
28th November 2005

heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from halo and C₁₋₄alkyl;

10) -R^aR⁴², wherein R⁴² is as defined hereinbefore;

11) -R^bR⁴², wherein R⁴² is as defined hereinbefore;

12) -R^cR⁴², wherein R⁴² is as defined hereinbefore;

13) -R^xX⁶R⁴², wherein X⁶ represents: -O-, -C(O)-, -S-, -SO-, -SO₂-, -OC(O)-, -NR⁴⁷C(O)-, -C(O)NR⁴⁸-, C(O)ONR⁴⁸-, -SO₂NR⁴³-, -NR⁵⁰SO₂- or -NR⁵¹-, wherein R⁴⁷, R⁴⁸, R⁴⁹, R⁵⁰ and R⁵¹ each independently represents hydrogen, C₁₋₃alkyl, hydroxyC₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl, and R⁴² is as defined hereinbefore;

14) -R^kX⁷R⁴², wherein X⁷ represents: -O-, C(O)-, -S-, -SO-, -SO₂-, -NR⁷³C(O)-, -C(O)NR⁷⁴-, C(O)ONR⁷⁴-, -SO₂NR⁷⁵-, -NR⁷⁶SO₂- or -NR⁷⁷-, wherein R⁷³, R⁷⁴, R⁷⁵, R⁷⁶ and R⁷⁷ each independently represents hydrogen, C₁₋₃alkyl, hydroxyC₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl, and R⁴² is as defined hereinbefore;

15) -R^mX⁸R⁴², wherein X⁸ represents: -O-, -C(O)-, -S-, -SO-, -SO₂-, -NR⁵⁷C(O)-, -C(O)NR⁵⁸-, -SO₂NR⁵⁹-, -NR⁶⁰SO₂- or -NR⁶¹-, wherein R⁵⁷, R⁵⁸, R⁵⁹, R⁶⁰ and R⁶¹ each independently represents hydrogen, C₁₋₃alkyl, hydroxyC₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl, and R⁴² is as defined hereinbefore;

16) -RⁿX⁹RⁿR⁴², wherein X⁹ represents: -O-, -C(O)-, -S-, -SO-, -SO₂-, -NR⁶²C(O)-, -C(O)NR⁶³-, C(O)ONR⁶³-, -SO₂NR⁶⁴-, -NR⁶⁵SO₂- or -NR⁶⁶-, wherein R⁶², R⁶³, R⁶⁴, R⁶⁵ and R⁶⁶ each independently represents hydrogen, C₁₋₃alkyl, hydroxyC₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl, and R⁴² is as defined hereinbefore;

17) -R^pX⁹-R^pR⁴¹, wherein X⁹ and R⁴¹ are as defined hereinbefore;

18) C₂₋₅alkenyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, amino, C₁₋₄alkylamino, N,N-di(C₁₋₄alkyl)amino, aminosulphonyl, N-C₁₋₄alkylaminosulphonyl and N,N-di(C₁₋₄alkyl)aminosulphonyl;

19) C₂₋₅alkynyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, amino, C₁₋₄alkylamino, N,N-di(C₁₋₄alkyl)amino, aminosulphonyl, N-C₁₋₄alkylaminosulphonyl and N,N-di(C₁₋₄alkyl)aminosulphonyl;

20) -RⁱX⁹R^rR⁴¹, wherein X⁹ and R⁴¹ are as defined hereinbefore;

21) -R^uX⁹R^uR⁴¹, wherein X⁹ and R⁴¹ are as defined hereinbefore; and

22) -R^vR⁶⁷(R^y)_q(X⁹)_rR⁶⁸, wherein X⁹ is as defined hereinbefore, q is 0 or 1, r is 0 or 1, and R⁶⁷ is a C₁₋₃alkylene group or a cyclic group selected from cyclopropyl, cyclobutyl, cyclopentylene,

Application No.
Amendment Dated
Reply to Office Action of

10/088,352
27th June 2005
28th November 2005

cyclohexylene or a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which C₁₋₃alkylene group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C₁₋₄alkoxy and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C₁₋₄cyanoalkyl, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkylsulphonylC₁₋₄alkyl, C₁₋₄alkoxycarbonyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkoxy, di(C₁₋₄alkyl)aminoC₁₋₄alkoxy and a group $-(O-)_f(C_{1-4}alkyl)_g$ ringD, wherein f is 0 or 1, g is 0 or 1 and ring D is a cyclic group selected from C₃₋₆cycloalkyl, aryl or 5-6-membered saturated or unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from halo and C₁₋₄alkyl; and R⁶⁸ is hydrogen, C₁₋₃alkyl, or a cyclic group selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which C₁₋₃alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, C₁₋₄alkoxy and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C₁₋₄cyanoalkyl, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkylsulphonylC₁₋₄alkyl, C₁₋₄alkoxycarbonyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkoxy, di(C₁₋₄alkyl)aminoC₁₋₄alkoxy and a group $-(O-)_f(C_{1-4}alkyl)_g$ ringD, wherein f is 0 or 1, g is 0 or 1 and ring D is a cyclic group selected from C₃₋₆cycloalkyl, aryl or 5-6-membered saturated or unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from halo and C₁₋₄alkyl; and wherein R^a, R^b, R^{b'}, R^c, R^{c'}, R^d, R^{d'}, R^e, R^{e'}, R^f, R^{f'}, R^g, R^{g'}, R^h, R^{h'}, Rⁱ and R^{i'} are independently selected from C₁₋₃alkylene groups optionally substituted by one or more substituents selected from hydroxy, halogeno, amino, R^a, R^b, R^c and R^d are independently selected from C₂₋₆alkenylene groups optionally substituted by one or more substituents selected from hydroxy, halogeno, amino, and Rⁱ may additionally be a bond; and R^f, R^{f'}, R^g and R^{g'} are independently selected from C₂₋₆alkynylene groups optionally substituted by one or more substituents selected from hydroxy, halogeno, amino; wherein a phosphate ester is a derivative of a hydroxy group present on one or more of R¹, R², R³ or R⁴; wherein functional group refers to reactive substituents selected from nitro, cyano, halo, oxo, $=CR^{78}R^{79}$, $C(O)R^{77}$, OR^{77} , $S(O)R^{77}$, $NR^{78}R^{79}$, $C(O)NR^{78}R^{79}$, $OC(O)NR^{78}R^{79}$, $=NOR^{77}$.


Application No.
Amendment Dated
Reply to Office Action of

10/088,352
27th June 2005
28th November 2005

$-\text{NR}^{77}\text{C}(\text{O})_x\text{R}^{78}$, $-\text{NR}^{77}\text{CONR}^{78}\text{R}^{79}$, $-\text{N}=\text{CR}^{78}\text{R}^{79}$, $\text{S}(\text{O})_y\text{NR}^{78}\text{R}^{79}$ or $-\text{NR}^{77}\text{S}(\text{O})_y\text{R}^{78}$ where R^{77} , R^{78} and R^{79} are independently selected from hydrogen, optionally substituted hydrocarbyl, optionally substituted heterocyclyl or optionally substituted C_{1-10} alkoxy, or R^{78} and R^{79} together form an optionally substituted ring which optionally contains further heteroatoms such as oxygen, nitrogen, S, $\text{S}(\text{O})$ or $\text{S}(\text{O})_2$, where x is an integer of 1 or 2, y is 0 or an integer of 1-3; and where optional substituents for hydrocarbyl, heterocyclyl or C_{1-10} alkoxy groups R^{77} , R^{78} and R^{79} as well as rings formed by R^{78} and R^{79} are halo, perhalo C_{1-10} alkyl, mercapto, thio C_{1-10} alkyl, hydroxy, carboxy, C_{1-10} alkoxy, heteroaryl, heteroaryloxy, C_{3-10} cycloalkyl, C_{3-10} cycloalkenyl, C_{3-10} cycloalkynyl, C_{2-10} alkenyloxy, C_{2-10} alkynyloxy, C_{1-10} alkoxy C_{1-10} alkoxy, aryloxy where the aryl group may be substituted by halo, nitro or hydroxy, cyano, nitro, amino, mono- or di- C_{1-10} alkyl amino, oximino or $\text{S}(\text{O})_y\text{R}^{90}$ where y is as defined above and R^{90} is a C_{1-10} alkyl; and wherein hydrocarbyl is selected from C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, aryl, ar C_{1-10} alkyl, C_{3-10} cycloalkyl, C_{3-10} cycloalkenyl or C_{3-10} cycloalkynyl; or C_{1-10} alkyl, C_{2-10} alkenyl or C_{2-10} alkynyl substituted with aryl, ar C_{1-10} alkyl, C_{3-10} cycloalkyl, C_{3-10} cycloalkenyl or C_{3-10} cycloalkynyl; or an aryl, heterocyclyl, C_{1-10} alkoxy, ar C_{1-10} alkyl, C_{3-10} cycloalkyl, C_{3-10} cycloalkenyl or C_{3-10} cycloalkynyl substituted with C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl or C_{1-10} alkoxy..

2-6. (cancelled)

7. (currently amended) A compound of formula (IA)



(IA)

according to claim 1, or a salt, or phosphate ester or amide thereof; wherein where X is O, or S, $\text{S}(\text{O})$ or $\text{S}(\text{O})_2$, NH or NR^{40} where R^{40} is hydrogen or C_{1-6} alkyl;

Application No.
Amendment Dated
Reply to Office Action of

10/088,352
27th June 2005
28th November 2005

R^5 is a group OR^{11} , $NR^{12}R^{13}$ or SR^{14} , where R^{11} , R^{12} and R^{13} are independently selected from hydrogen, optionally substituted hydrocarbyl or optionally substituted heterocyclic groups, and R^{12} and R^{13} may additionally form together with the nitrogen atom to which they are attached, an aromatic or non-aromatic heterocyclic ring which may contain further heteroatoms, R^8 and R^9 are independently selected from hydrogen, halo, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkoxymethyl, di(C_{1-4} alkoxy)methyl, C_{1-4} alkanoyl, trifluoromethyl, cyano, amino, C_{2-6} alkenyl, C_{2-6} alkynyl, a phenyl group, a benzyl group or a 5-6 membered heterocyclic group with 1-3 heteroatoms, selected independently from O, S and N, which heterocyclic group may be aromatic or non-aromatic and may be saturated, linked via a ring carbon or nitrogen atom, or unsaturated, linked via a ring carbon atom, and which phenyl, benzyl or heterocyclic group may bear on one or more ring carbon atoms up to 5 substituents selected from hydroxy, halogen, C_{1-3} alkyl, C_{1-3} alkoxy, C_{1-3} alkanoyloxy, trifluoromethyl, cyano, amino, nitro, C_{2-4} alkanoyl, C_{1-4} alkanoylamino, C_{1-4} alkoxycarbonyl, C_{1-4} alkylsulphonyl, C_{1-4} alkylsulphinyl, C_{1-4} alkylsulphonyl, carbamoyl, N- C_{1-4} alkylcarbamoyl, N,N-di(C_{1-4} alkyl)carbamoyl, aminesulphonyl, N- C_{1-4} alkylaminesulphonyl, N,N-di(C_{1-4} alkyl)aminesulphonyl, C_{1-4} alkylsulphonylamino, and a saturated heterocyclic group selected from morpholine, thiomorpholine, pyrrolidinyl, piperazinyl, piperidinyl, imidazolidinyl and pyrazolidinyl, which saturated heterocyclic group may bear 1 or 2 substituents selected from exo, hydroxy, halogen, C_{1-3} alkyl, C_{1-3} alkoxy, C_{1-3} alkanoyloxy, trifluoromethyl, cyano, amino, nitro and C_{1-4} alkoxycarbonyl, and

R^1 , R^2 , R^3 , R^4 are independently selected from, halo, cyano, nitro, trifluoromethyl, C_{1-3} alkyl, $-NR^{14}R^{15}$, wherein R^{14} and R^{15} , which may be the same or different, each represents hydrogen or C_{1-3} alkyl, or $-X^1R^{16}$, wherein X^1 represents a direct bond, $-O-$, $-CH_2-$, $-OCO-$, carbonyl, $-S-$, $-SO-$, $-SO_2-$, $-NR^{17}CO-$, $-CONR^{18}-$, $-SO_2NR^{19}-$, $-NR^{20}SO_2-$ or $-NR^{21}-$, wherein R^{17} , R^{18} , R^{19} , R^{20} and R^{21} each independently represents hydrogen, C_{1-3} alkyl or C_{1-3} alkoxy C_{2-3} alkyl, and R^{18} is selected from one of the following seventeen groups:

- 1') hydrogen or C_{1-5} alkyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro or amino;[[.]]
- 2') C_{1-5} alkyl X^2COR^{22} ; wherein X^2 represents $-O-$ or $-NR^{23}-[[.]]$ in which R^{23} represents hydrogen, C_{1-3} alkyl or C_{1-3} alkoxy C_{2-3} alkyl, and R^{22} represents C_{1-3} alkyl, $-NR^{24}R^{25}$ or $-OR^{26}$, wherein R^{24} , R^{25} and R^{26} which may be the same or different each represents hydrogen, C_{1-3} alkyl or C_{1-3} alkoxy C_{2-3} alkyl;[[.]]
- 3') C_{1-5} alkyl X^3R^{27} ; wherein X^3 represents $-O-$, $-S-$, $-SO-$, $-SO_2-$, $-OCO-$, $-NR^{28}CO-$, $-CONR^{29}-$, $-SO_2NR^{30}-$, $-NR^{31}SO_2-$ or $-NR^{32}-$, wherein R^{28} , R^{29} , R^{30} , R^{31} and R^{32} each independently

Application No.
Amendment Dated
Reply to Office Action of

10/088,352
27th June 2005
28th November 2005

represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl, and R²⁷ represents hydrogen, C₁₋₃alkyl, cyclopentyl, cyclohexyl or a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms[[.]] selected independently from O, S and N, which C₁₋₃alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C₁₋₄alkoxy and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, C₁₋₄alkyl, C₁₋₄hydroxyalkyl and C₁₋₄alkoxy[[.]]:

4') C₁₋₆alkylX⁴C₁₋₆alkylX⁵R³⁵; wherein X⁴ and X⁵ which may be the same or different are each -O-, -S-, -SO-, -SO₂-, -NR³⁶CO-, -CONR³⁷-, -SO₂NR³⁸-, -NR³⁸SO₂- or -NR⁴⁰-, wherein R³⁶, R³⁷, R³⁸, R³⁹ and R⁴⁰ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl, and R³⁵ represents hydrogen or C₁₋₃alkyl;

5') R⁴¹; wherein R⁴¹ is a 5-6-membered saturated heterocyclic group, linked via carbon or nitrogen, with 1-2 heteroatoms[[.]] selected independently from O, S and N, which heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl and C₁₋₄alkylsulphonylC₁₋₄alkyl;

6') C₁₋₅alkylR⁴¹; wherein R⁴¹ is as defined hereinbefore;

7') C₂₋₅alkenylR⁴¹; wherein R⁴¹ is as defined hereinbefore;

8') C₂₋₅alkynylR⁴¹; wherein R⁴¹ is as defined hereinbefore;

9') R⁴²; wherein R⁴² represents a phenyl group or a 5-6-membered aromatic heterocyclic group, linked via carbon or nitrogen, with 1-3 heteroatoms selected from O, N and S, which phenyl or aromatic heterocyclic group may carry up to 5 substituents on an available carbon atom selected from hydroxy, halogeno, amino, C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄hydroxyalkyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, C₁₋₄hydroxyalkoxy, carboxy, trifluoromethyl, cyano, -CONR⁴³R⁴⁴ and -NR⁴⁵COR⁴⁶, wherein R⁴³, R⁴⁴, R⁴⁵ and R⁴⁶, which may be the same or different, each represents hydrogen, C₁₋₄alkyl or C₁₋₃alkoxyC₂₋₃alkyl;

10') C₁₋₅alkylR⁴²; wherein R⁴² is as defined hereinbefore;

11') C₂₋₅alkenylR⁴²; wherein R⁴² is as defined hereinbefore;

12') C₂₋₅alkynylR⁴²; wherein R⁴² is as defined hereinbefore;

13') C₁₋₅alkylX⁶R⁴²; wherein X⁶ represents -O-, -S-, -SO-, -SO₂-, -NR⁴⁷CO-, -CONR⁴⁸-, -SO₂NR⁴⁹-, -NR⁵⁰SO₂- or -NR⁵¹-, wherein R⁴⁷, R⁴⁸, R⁴⁹, R⁵⁰ and R⁵¹ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl, and R⁴² is as defined hereinbefore;


14') C₂₋₅alkenylX⁷R⁴²; wherein X⁷ represents -O-, -S-, -SO-, -SO₂-, -NR⁵²CO-, -CONR⁵³-, -SO₂NR⁵⁴-, -NR⁵⁵SO₂- or -NR⁵⁶-, wherein R⁵², R⁵³, R⁵⁴, R⁵⁵ and R⁵⁶ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl, and R⁴² is as defined hereinbefore;

Application No.
Amendment Dated
Reply to Office Action of

10/088,352
27th June 2005
28th November 2005

- 15') $C_{2-5}alkynylX^8R^{42}$; wherein X^8 represents $-O-$, $-S-$, $-SO-$, $-SO_2-$, $-NR^{57}CO-$, $-CONR^{58}-$, $-SO_2NR^{59}-$, $-NR^{60}SO_2-$ or $-NR^{61}-$, wherein R^{57} , R^{58} , R^{59} , R^{60} and R^{61} each independently represents hydrogen, $C_{1-3}alkyl$ or $C_{1-3}alkoxyC_{2-3}alkyl$, and R^{42} is as defined hereinbefore;
16') $C_{1-3}alkylX^9C_{1-3}alkylR^{42}$; wherein X^9 represents $-O-$, $-S-$, $-SO-$, $-SO_2-$, $-NR^{62}CO-$, $-CONR^{63}-$, $-SO_2NR^{64}-$, $-NR^{65}SO_2-$ or $-NR^{66}-$, wherein R^{62} , R^{63} , R^{64} , R^{65} and R^{66} each independently represents hydrogen, $C_{1-3}alkyl$ or $C_{1-3}alkoxyC_{2-3}alkyl$, and R^{42} is as defined hereinbefore; and
17') $C_{1-3}alkylX^9C_{1-3}alkylR^{41}$; wherein X^9 and R^{41} are as defined hereinbefore;
and R^6 and R^7 are hydrogen or $C_{1-4}alkyl$.


8. (currently amended) A compound according to claim 7, or a salt or phosphate ester thereof wherein R^6 and R^7 are hydrogen.
9. (cancelled)
10. (currently amended) A compound according to claim 1 [[6]] or a salt or phosphate ester thereof, wherein R^5 is selected from a group OR^{11} where R^{11} is hydrogen or $C_{1-4}alkyl$; or a group $NR^{12}R^{13}$ where one of R^{12} or R^{13} is hydrogen and the other is optionally substituted $C_{1-6}alkyl$, optionally substituted aryl or optionally substituted heterocyclyl, or R^{12} and R^{13} together with the nitrogen atom to which they are attached form a heterocyclic ring.
11. (previously presented) A compound according to claim 10, which is a phosphate ester of a compound of formula (I).
12. (currently amended) A method for preparing a compound of formula (I) as defined in claim 1 which method comprises reacting a compound of formula (II)



Application No. 10/088,352
 Amendment Dated 27th June 2005
 Reply to Office Action of 28th November 2005

(II)

where X, R⁸ and R⁹ are as defined in claim 1, R¹, R², R³, R⁴ are groups R¹, R², R³, R⁴ as defined in claim 1 respectively; and R⁵ is a leaving group, with a compound of formula (III)



where R⁸ and R⁷ are as defined in claim 1 and R⁵ is a group R⁵ as defined in claim 1.

13. (cancelled)

14. (currently amended) A method for treating colorectal or breast cancer in a warm blooded animal, in need of such treatment, which comprises administering to said animal an effective amount of a compound of formula (I), or a salt[[.]] or phosphate ester, or amide thereof.

15. (currently amended) A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1, or a salt[[.]] or phosphate ester, or amide thereof, in combination with a pharmaceutically acceptable carrier.

16. (currently amended) A compound according to claim 10, or a salt[[.]] or phosphate ester or amide thereof; where
 R⁵ is a group OR¹¹, NR¹²R¹³ or SR¹¹ where R¹¹ is hydrogen or C₁₋₄alkyl, and where one of R¹² and R¹³ is hydrogen and the other is C₁₋₆alkyl optionally substituted with one or more groups selected from hydroxy, trifluoromethyl, C₁₋₃alkoxy, cyano, amino, mono- or di-C₁₋₄alkylamino, C₁₋₄alkylthio, C₃₋₆cycloalkyl or heterocyclyl optionally substituted with C₁₋₄alkyl; or one of R¹² and R¹³ is hydrogen and the other is a heterocyclic group as well as dioxides thereof, C₃₋₆cycloalkyl or a phenyl group any of which may be substituted with one or more groups selected from halo, nitro, C₁₋₄alkyl or C₁₋₄alkoxy, and R¹² and R¹³ may additionally form together with the nitrogen atom to which they are attached, morpholine or piperidine;[[.]]
 R⁶ and R⁷ are independently selected from hydrogen or C₁₋₄alkyl;
 R⁸ and R⁹ are independently selected from hydrogen, halo, C₁₋₄alkoxy, trifluoromethyl, cyano or phenyl.

Application No.
Amendment Dated
Reply to Office Action of

10/088,852
27th June 2005
28th November 2005

17. (currently amended) A compound according to claim 16, or a salt or phosphate ester thereof, wherein X is NH or O.

18. (currently amended) A compound according to claim 16, or a salt or phosphate ester thereof, wherein

R¹ is hydrogen; [I, II]

R² is halo, cyano, nitro, trifluoromethyl, C₁₋₃alkyl, -NR¹⁴R¹⁵, wherein R¹⁴ and R¹⁵, which may be the same or different, each represents hydrogen or C₁₋₃alkyl, or a group -X¹R¹⁶ where X¹ is oxygen and R¹⁶ is a group (1); ~~as defined in claim 6~~,

R³ is a group -X¹R¹⁶ where X¹ is oxygen and R¹⁶ is a group selected from group (1), (3), (6) and (10); ~~as defined in claim 6~~

and R⁴ is hydrogen, halo, C₁₋₄alkyl, or C₁₋₄alkoxy;

wherein group (1) is hydrogen or C₁₋₃alkyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, oxiranyl, fluoro, chloro, bromo, amino, C₁₋₃alkyl and trifluoromethyl;

group (3) is -R^bX³R²⁷; wherein X³ represents -O-, C(O)-S-, -SO-, -SO₂-, -OC(O)-, -NR²⁸C(O)-, -NR²⁸C(O)O-, -C(O)NR²⁹-, C(O)O)NR²⁹-, -SO₂NR³⁰-, -NR³¹SO₂- or -NR³²- wherein R²⁸, R²⁹, R³⁰,

R³¹ and R³² each independently represents hydrogen, C₁₋₃alkyl, hydroxy C₁₋₄alkyl or C₁₋₃alkoxy C₂₋₃alkyl, and R²⁷ represents hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl or a 5-6-membered saturated heterocyclic group with 1-2

heteroatoms, selected independently from O, S and N, which C₁₋₆alkyl group may bear 1, 2 or 3 substituents selected from oxo, hydroxy, halogeno, cyclopropyl, amino, C₁₋₄alkylamino,

C₁₋₄alkanoyldi-C₁₋₄alkylamino, C₁₋₄alkylthio, C₁₋₄alkoxy and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C₁₋₄cyanoalkyl, C₁₋₄alkyl,

C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxy C₁₋₄alkyl, C₁₋₄alkylsulphonyl C₁₋₄alkyl, C₁₋₄alkoxycarbonyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, C₁₋₄alkylamino C₁₋₄alkyl,

di(C₁₋₄alkyl)amino C₁₋₄alkyl, C₁₋₄alkylamino C₁₋₄alkoxy, di(C₁₋₄alkyl)amino C₁₋₄alkoxy and a group

-(-O-)_f(R^b)_gD, wherein f is 0 or 1, g is 0 or 1 and D is a cyclic group selected from C₃₋₆cycloalkyl group, an aryl group or a 5-6-membered saturated or unsaturated heterocyclic group with 1-2

heteroatoms selected independently from O, S and N, which cyclic group may bear one or more substituents selected from halo or C₁₋₄alkyl;

group (6) is -R^aR⁴¹; wherein R⁴¹ is a 4-6-membered cycloalkyl or saturated heterocyclic ring,

linked via carbon or nitrogen with 1-2 heteroatoms selected independently from O, S and N, which cycloalkyl or heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy,

Application No.
Amendment Dated
Reply to Office Action of

10/088,852
27th June 2005
28th November 2005

halogeno, cyano, C₁₋₄alkyl, hydroxyl, C₁₋₄alkyl, cyanoC₁₋₄alkyl, cyclopropyl, C₁₋₄alkylsulphonylC₁₋₄alkyl, C₁₋₄alkoxycarbonyl, carboxamido, C₁₋₄aminoalkyl, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, C₁₋₄alkanoyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkoxy, di(C₁₋₄alkyl)aminoC₁₋₄alkoxy nitro, amino, C₁₋₄alkoxy, C₁₋₄hydroxyalkoxy, carboxy, trifluoromethyl, -C(O)NR⁴³R⁴⁴, -NR⁴⁵C(O)R⁴⁶ wherein R⁴³, R⁴⁴, R⁴⁵ and R⁴⁶ which may be the same or different, each represents hydrogen, C₁₋₄alkyl, hydroxylC₁₋₄alkyl or C₁₋₃alkoxyC₂₋₃alkyl, and a group -(-O-)_f(C₁₋₄alkyl)_gringD, wherein f is 0 or 1, g is 0 or 1 and D is a cyclic group selected from C₃₋₆cycloalkyl, aryl or 5-6-membered saturated or unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from halo and C₁₋₄alkyl; group (10) is -R⁴²R⁴² wherein R⁴² represents a phenyl group or a 5-6-membered aromatic heterocyclic group, linked via carbon or nitrogen, with 1-3 heteroatoms selected from O, N and S, which phenyl or aromatic heterocyclic group may carry up to 5 substituents selected from hydroxy, nitro, halogeno, amino, C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄hydroxyalkyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, C₁₋₄hydroxyalkoxy, oxo, cyanoC₁₋₄alkyl, cyclopropyl, C₁₋₄alkylsulphonylC₁₋₄alkyl, C₁₋₄alkoxycarbonyl, di(C₁₋₄alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, C₁₋₄alkanoyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkoxy, di(C₁₋₄alkyl)aminoC₁₋₄alkoxy, carboxy, carboxamido, trifluoromethyl, cyano, -C(O)NR⁶⁹R⁷⁰, -NR⁷¹C(O)R⁷², wherein R⁶⁹, R⁷⁰, R⁷¹ and R⁷² which may be the same or different, each represents hydrogen, C₁₋₄alkyl, hydroxylC₁₋₄alkyl or C₁₋₃alkoxyC₂₋₃alkyl, and a group -(-O-)_f(C₁₋₄alkyl)_gringD wherein f is 0 or 1, g is 0 or 1 and ring D is a cyclic group selected from C₃₋₆cycloalkyl, aryl or 5-6-membered saturated or unsaturated heterocyclic group with 1-2 heteroatoms selected independently from O, S and N, which cyclic group may bear one or more substituents selected from halo and C₁₋₄alkyl; and R^a, R^b, R^c and R^d are independently selected from C₁₋₈alkylene groups optionally substituted by one or more substituents selected from hydroxy, halogeno, amino.

19. (currently amended) A compound according to claim 16, or a salt or phosphate ester thereof, wherein R² and R³ are independently methoxy or 3,3,3-trifluoroethoxy.

20. (currently amended) A compound according to claim 16, or a salt or phosphate ester thereof, wherein R³ is 3-morpholinopropoxy.

21. (currently amended) A compound according to claim 16, or a salt or phosphate ester thereof, wherein R⁸ and R⁹ are both hydrogen.

Application No.
Amendment Dated
Reply to Office Action of

10/088,852
27th June 2005
28th November 2005

22. (currently amended) A compound according to claim 16, or a salt or phosphate ester thereof, wherein R⁶ and R⁷ are both hydrogen.
23. (new) A compound according to claim 1 or a salt or phosphate ester thereof wherein X is NH or O.
24. (new) A compound according to claim 1 or a salt or phosphate ester thereof wherein R⁶ and R⁷ are independently hydrogen or C₁₋₄alkyl.
25. (new) A compound according to claim 1 or a salt or phosphate ester thereof wherein R⁸ and R⁹ are independently hydrogen, halo, C₁₋₄alkoxy, cyano, trifluoromethyl or phenyl.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT.
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.